Table 1 Characteristics of the included randomized controlled trials
Year | Author | Country | Liver disease | Disease etiology | Cell type | Cell dosage | Times of treatment | Administration route | Patient number | Median age | Follow-up time | Adverse event | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Exp group | Con group | Exp group | Con group | |||||||||||
2021 | Shi [27] | China | Decompensated cirrhosis | HBV | Allogeneic UC-MSCs | 1 × 106 /kg | Three | Intravenous injection | 108 | 111 | 47 | 48 | 75 month | Fever |
2021 | Schacher [26] | Brazil | ACLF | Alcohol, HCV, HBV, NASH | Allogeneic BM-MSCs | 1 × 106/kg | Two | Intravenous injection | 4 | 5 | 55.8 | 53.4 | 90 day | No |
2019 | Xu [19] | China | ACLF | HBV | Allogeneic UC-MSCs | 1 × 105/kg | Four | Intravenous injection | 30 | 30 | 40.67 | 44.67 | 48 week | Fever |
2017 | Lin [10] | China | ACLF | HBV | Allogeneic BM-MSCs | (1.0–10) × 105/kg | Four | Intravenous injection | 56 | 54 | 40 | 42.8 | 24 week | Fever |
2016 | Suk [25] | South Korea | Decompensated Cirrhosis | Alcohol | Autologous BM-MSCs | 5 × 107/kg | One | Hepatic arterial injection | 18 | 18 | 53.1 | 53.7 | 12 month | Fever |
2016 | Suk [25] | South Korea | Decompensated Cirrhosis | Alcohol | Autologous BM-MSCs | 6 × 107/kg | Two | Hepatic arterial injection | 19 | 18 | 54.4 | 53.7 | 12 month | Fever |
2014 | Xu [24] | China | Cirrhosis | HBV | Autologous BM-MSCs | (0.75 ± 0.5) × 106 | One | Hepatic arterial injection | 20 | 19 | 44 | 45 | 24 week | Fever |
2014 | Salama [9] | Egypt | Decompensated cirrhosis | HCV | Autologous BM-MSCs | 1 × 106/kg | One | Intravenous injection | 20 | 20 | 50.27 | 50.9 | 6 month | No |
2013 | Mohamadnejad [23] | Iran | Decompensated cirrhosis | PBC, HBV, HCV, AIH | Autologous BM-MSCs | (1.2–2.95) × 108 | One | Intravenous injection | 14 | 11 | 43.1 | 34.6 | 12 month | NA |
2012 | Zhang [8] | China | Decompensated cirrhosis | HBV | Allogeneic UC-MSCs | 0.5 × 106/kg | Three | Intravenous injection | 30 | 15 | 48 | 47 | 48 week | No |
2012 | Shi [22] | China | ACLF | HBV | Allogeneic UC-MSCs | 0.5 × 107/kg | Three | Intravenous injection | 24 | 19 | 40 | 45 | 48 week | No |
2012 | El-Ansary [21] | Egypt | Cirrhosis | HCV | Autologous BM-MSCs | 1 × 106/kg | One | Intravenous injection | 15 | 10 | 48 | 51.6 | 6 month | NA |
2011 | Peng [11] | China | ACLF | HBV | Autologous BM-MSCs | (3.4 ± 3.8) × 108 | One | Hepatic arterial injection | 53 | 105 | 42.19 | 42.2 | 192 week | No |